BP
CORT icon

Ballentine Partners’s Corcept Therapeutics CORT Stock Holding History

Ballentine Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Buy
+4,038
New +$244K ﹤0.01% 712
2025
Q4 		– Sell
-4,222
Closed -$351K – 1023
2025
Q3 		$351K Buy
4,222
+128
+3% +$9.26K ﹤0.01% 645
2025
Q2 		$301K Buy
4,094
+72
+2% +$5.22K ﹤0.01% 689
2025
Q1 		$459K Buy
4,022
+48
+1% +$2.92K 0.01% 472
2024
Q4 		$200K Buy
+3,974
New +$208K ﹤0.01% 787

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ballentine Partners's CORT Position: Q2 2026 in Review

Ballentine Partners opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 4,038 shares worth $351K. The stake represents ﹤0.01% of the portfolio and ranks #712 among its holdings. This is a return to the name: Ballentine Partners previously reported a position in CORT as recently as Q3 2025.

Ballentine Partners first reported a position in CORT in Q4 2024 and has held it in 5 quarters since. The position peaked at $459K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Ballentine Partners held 4,038 shares of Corcept Therapeutics worth $351K as of Q2 2026.
  • Corcept Therapeutics was a new Ballentine Partners position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #712 holding.
  • Ballentine Partners first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Ballentine Partners's Corcept Therapeutics position peaked at $459K in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.